Novel LRRK2 GTP-binding inhibitors reduced degeneration in Parkinson's disease cell and mouse models (Q39164937)

9 September 2017

title

Novel LRRK2 GTP-binding inhibitors reduced degeneration in Parkinson's disease cell and mouse models (English)

1 reference

9 September 2017

1 reference

Tianxia Li

1

1 reference

9 September 2017

Dejun Yang

2

1 reference

9 September 2017

Shijun Zhong

3

1 reference

9 September 2017

Joseph M Thomas

4

1 reference

9 September 2017

Fengtian Xue

5

1 reference

9 September 2017

Jingnan Liu

6

1 reference

9 September 2017

Lingbo Kong

7

1 reference

9 September 2017

Pamela Voulalas

8

1 reference

9 September 2017

Hazem E Hassan

9

1 reference

9 September 2017

Jae-Sung Park

10

1 reference

9 September 2017

Alexander D MacKerell

11

1 reference

9 September 2017

Wanli W Smith

12

1 reference

9 September 2017

publication date

3 July 2014

1 reference

9 September 2017

published in

Human Molecular Genetics

1 reference

9 September 2017

volume

23

1 reference

9 September 2017

issue

23

1 reference

9 September 2017

page(s)

6212-6222

1 reference

Rationally designed multi-targeted agents against neurodegenerative diseases

9 September 2017

cites work

1 reference

Leucine-rich repeat kinase 2 inhibitors: a patent review (2006 - 2011).

21 January 2018

1 reference

Cloning of the gene containing mutations that cause PARK8-linked Parkinson's disease

21 January 2018

1 reference

Mutations in LRRK2 cause autosomal-dominant parkinsonism with pleomorphic pathology

21 January 2018

1 reference

Leucine-rich repeat kinase 2 (LRRK2): a key player in the pathogenesis of Parkinson's disease

21 January 2018

1 reference

Mutations in LRRK2 as a cause of Parkinson's disease

21 January 2018

1 reference

Zeroing in on LRRK2-linked pathogenic mechanisms in Parkinson's disease.

21 January 2018

1 reference

LRRK2 in Parkinson's disease: genetic and clinical studies from patients

21 January 2018

1 reference

Models for LRRK2-Linked Parkinsonism

21 January 2018

1 reference

The role of leucine-rich repeat kinase 2 (LRRK2) in Parkinson's disease

21 January 2018

1 reference

Leucine-rich repeat kinase 2 (LRRK2) as a potential therapeutic target in Parkinson's disease

21 January 2018

1 reference

Parkinson disease-associated mutation R1441H in LRRK2 prolongs the "active state" of its GTPase domain

21 January 2018

1 reference

Characterization of a selective inhibitor of the Parkinson's disease kinase LRRK2.

21 January 2018

1 reference

Inhibitors of leucine-rich repeat kinase-2 protect against models of Parkinson's disease

21 January 2018

1 reference

Inhibitors of LRRK2 kinase attenuate neurodegeneration and Parkinson-like phenotypes in Caenorhabditis elegans and Drosophila Parkinson's disease models

21 January 2018

1 reference

Kinase activity of mutant LRRK2 mediates neuronal toxicity

21 January 2018

1 reference

The R1441C mutation of LRRK2 disrupts GTP hydrolysis

21 January 2018

1 reference

Structure of the ROC domain from the Parkinson's disease-associated leucine-rich repeat kinase 2 reveals a dimeric GTPase

21 January 2018

1 reference

Autophosphorylation in the leucine-rich repeat kinase 2 (LRRK2) GTPase domain modifies kinase and GTP-binding activities

21 January 2018

1 reference

Kinetic mechanistic studies of wild-type leucine-rich repeat kinase 2: characterization of the kinase and GTPase activities

21 January 2018

1 reference

Development of a mechanism-based high-throughput screen assay for leucine-rich repeat kinase 2--discovery of LRRK2 inhibitors

21 January 2018

1 reference

GTPase activity regulates kinase activity and cellular phenotypes of Parkinson's disease-associated LRRK2

21 January 2018

1 reference

GTPase activity plays a key role in the pathobiology of LRRK2.

21 January 2018

1 reference

Development of extracellular signal-regulated kinase inhibitors.

21 January 2018

1 reference

Identification and validation of human DNA ligase inhibitors using computer-aided drug design

21 January 2018

1 reference

LRRK1 protein kinase activity is stimulated upon binding of GTP to its Roc domain

21 January 2018

1 reference

Mutant LRRK2(R1441G) BAC transgenic mice recapitulate cardinal features of Parkinson's disease

21 January 2018

1 reference

Enhanced striatal dopamine transmission and motor performance with LRRK2 overexpression in mice is eliminated by familial Parkinson's disease mutation G2019S

21 January 2018

1 reference

Common genetic variation in the HLA region is associated with late-onset sporadic Parkinson's disease

21 January 2018

1 reference

LRRK2 inhibition attenuates microglial inflammatory responses

21 January 2018

1 reference

Parkinson's disease-linked LRRK2 is expressed in circulating and tissue immune cells and upregulated following recognition of microbial structures

21 January 2018

1 reference

The IkappaB kinase family phosphorylates the Parkinson's disease kinase LRRK2 at Ser935 and Ser910 during Toll-like receptor signaling

21 January 2018

1 reference

Leprosy Susceptibility: Genetic Variations Regulate Innate and Adaptive Immunity, and Disease Outcome

21 January 2018

1 reference

The kinase LRRK2 is a regulator of the transcription factor NFAT that modulates the severity of inflammatory bowel disease

21 January 2018

1 reference

LRRK2 is involved in the IFN-gamma response and host response to pathogens

21 January 2018

1 reference

Phosphorylation-dependent 14-3-3 binding to LRRK2 is impaired by common mutations of familial Parkinson's disease

21 January 2018

1 reference

Reevaluation of phosphorylation sites in the Parkinson disease-associated leucine-rich repeat kinase 2

21 January 2018

1 reference

Consideration of molecular weight during compound selection in virtual target-based database screening

21 January 2018

1 reference

Identification of non-phosphate-containing small molecular weight inhibitors of the tyrosine kinase p56 Lck SH2 domain via in silico screening against the pY 3 binding site.

21 January 2018

1 reference

Characterization of ATP-independent ERK inhibitors identified through in silico analysis of the active ERK2 structure

21 January 2018

1 reference

CHARMM: the biomolecular simulation program

21 January 2018

1 reference

Scalable molecular dynamics with NAMD

21 January 2018

1 reference

LRRK2 kinase activity mediates toxic interactions between genetic mutation and oxidative stress in a Drosophila model: suppression by curcumin

21 January 2018

1 reference

Human alpha-synuclein-harboring familial Parkinson's disease-linked Ala-53 --> Thr mutation causes neurodegenerative disease with alpha-synuclein aggregation in transgenic mice

21 January 2018

1 reference

Synphilin-1 attenuates neuronal degeneration in the A53T alpha-synuclein transgenic mouse model

21 January 2018

1 reference

Binding Response: A Descriptor for Selecting Ligand Binding Site on Protein Surfaces

21 January 2018

1 reference

21 January 2018

Identifiers

DOI

10.1093/HMG/DDU341

1 reference

9 September 2017

1 reference